MarketPulse

navenibart

3 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Biocryst Pharmaceuticals, Inc.

BioCryst Lands $70M Deal, Reports ORLADEYO Growth Ahead of Navenibart Catalyst

BioCryst posts 11% ORLADEYO revenue growth to $148.3M in Q1 2026, inks $70M European licensing deal for navenibart with up to $275M in milestones.
BCRXrevenue growthclinical trial
GlobeNewswire Inc.GlobeNewswire Inc.··Na

BioCryst Lands $70M European Deal for Hereditary Angioedema Drug

BioCryst secures $70M upfront plus $275M milestone payments for navenibart European rights, reinforcing strategy to focus on U.S. commercialization.
BCRXPhase 3 clinical trialORLADEYO
GlobeNewswire Inc.GlobeNewswire Inc.··Na

BioCryst Achieves Historic Profitability as ORLADEYO Revenue Surges 38%

BioCryst achieved historic profitability with ORLADEYO revenue surging 38% to $601.8 million. FDA approval for pediatric formulation and Astria acquisition expand HAE treatment portfolio.
BCRXFDA approvalprofitability